Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, TWSE ticker: 1795.TT) and Finland headquartered Orion Corporation today announced that they have entered into an exclusive marketing and distribution agreement on 2 branded products indicated for the treatment of Parkinson’s disease, Stalevo® and Comtan®, in the Asia Pacific region. The agreement provides full sales and marketing control over the brands in basically every major Asian market including Taiwan, Korea, Hong Kong, Philippines, Vietnam, Indonesia and Bangladesh.